Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
58 participants
INTERVENTIONAL
2017-06-05
2020-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
NCT01464177
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT06344130
Trial of Hypofractionated Radiation Therapy for Glioblastoma
NCT02206230
Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.
NCT04610229
Treatment of High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial
NCT03082846
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hypofractionated radiation therapy
Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.
After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles.
Hypofractionated radiation therapy
Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hypofractionated radiation therapy
Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* WHO performance status of 2 or less and adequate hematologic, renal, and hepatic function.
Exclusion Criteria
* Previous history of radiotherapy in the head and neck region (except initial larynx tumor - T1, T2 / N0M0).
* Specific severe, active co-morbidities
* Tumor located in the brainstem
* Presence of leptomeningeal carcinomatosis
* Multicentric tumor
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto do Cancer do Estado de São Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gustavo Nader Marta
Radiation Oncologist and Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto do Cancer do Estado de São Paulo (ICESP) - FMUSP
São Paulo, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hypofractionated GBM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.